公开(公告)号：US20160347717A1

公开(公告)日：2016-12-01

申请号：US15167373

申请日：2016-05-27

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mark BOCK ,  Ming-Hong HAO ,  Manav KORPAL ,  Vijay Kumar NYAVANANDI ,  Xiaoling PUYANG ,  Susanta SAMAJDAR ,  Peter Gerard SMITH ,  John WANG ,  Guo Zhu ZHENG ,  Ping ZHU

IPC: C07D231/56 ,  C07D401/14 ,  C07D403/06 ,  C07D401/06 ,  C07D403/12 ,  C07D471/14

CPC classification number: C07D231/56 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D471/14

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

Abstract translation: 本文公开了化合物或其药学上可接受的盐，以及通过向有需要的受试者施用治疗有效量的化合物或其药学上可接受的盐来使用该化合物治疗乳腺癌的方法。 乳腺癌可能是ER阳性乳腺癌，和/或需要治疗的受试者可以表达突变型ER-α蛋白。

公开(公告)号：US20180141913A1

公开(公告)日：2018-05-24

申请号：US15821367

申请日：2017-11-22

Applicant: EISAI R & D MANAGEMENT CO., LTD.

Inventor： Mark BOCK ,  Ming-Hong HAO ,  Manav KORPAL ,  Vijay Kumar NYAVANANDI ,  Xiaoling PUYANG ,  Susanta SAMAJDAR ,  Peter Gerard SMITH ,  John WANG ,  Guo Zhu ZHENG ,  Ping ZHU ,  Lorna Helen MITCHELL ,  Nicholas LARSEN ,  Nathalie RIOUX ,  Sudeep PRAJAPATI ,  Dominic REYNOLDS ,  Morgan O'SHEA ,  Thiwanka SAMARAKOON

IPC: C07D231/56 ,  C07D401/14 ,  C07D401/10 ,  C07D413/12 ,  C07D413/14 ,  A61P35/00

CPC classification number: C07D231/56 ,  A61P35/00 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

公开(公告)号：US20210113537A1

公开(公告)日：2021-04-22

申请号：US16493931

申请日：2018-03-16

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Craig D. KARR ,  Manav KORPAL ,  Nathalie RIOUX ,  Peter Gerard SMITH

IPC: A61K31/445 ,  A61K31/519 ,  A61K45/06 ,  A61P35/00

Abstract: Provided herein is a combination therapy useful for the treatment breast cancer. The combination comprises an ER-alpha inhibitor and a CDK 4/6 inhibitor.

公开(公告)号：US20180127378A1

公开(公告)日：2018-05-10

申请号：US15713107

申请日：2017-09-22

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mark BOCK ,  Ming-Hong HAO ,  Manav KORPAL ,  Vijay Kumar NYAVANANDI ,  Xiaoling PUYANG ,  Susanta SAMAJDAR ,  Peter Gerard SMITH ,  John WANG ,  Guo Zhu ZHENG ,  Ping ZHU

IPC: C07D231/56 ,  C07D401/14 ,  C07D403/12 ,  C07D403/06 ,  C07D471/14 ,  C07D401/06

CPC classification number: C07D231/56 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D471/14

Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.